Mark Connolly
About Mark Connolly
Mark Connolly serves as the Director of Strategy at Tessera Therapeutics, a position he has held since 2021. He has extensive experience in biotechnology equity research, having worked at UBS and Credit Suisse, and has a strong academic background in accounting and economics from the University of Connecticut.
Work at Tessera Therapeutics
Mark Connolly has served as the Director of Strategy at Tessera Therapeutics since 2021. In this role, he focuses on developing and implementing strategic initiatives that align with the company's goals in the biotechnology sector. His experience in equity research and strategic planning contributes to Tessera's mission of advancing genetic medicine.
Previous Experience in Biotechnology Equity Research
Before joining Tessera Therapeutics, Mark Connolly worked at Credit Suisse as Vice President in Small and Mid-Cap Biotechnology Equity Research from 2017 to 2021. He also held the position of Equity Research Associate at UBS, focusing on Smid Cap Biotechnology from 2016 to 2017. His roles involved analyzing market trends and providing insights to support investment decisions in the biotechnology field.
Early Career in Accounting and Research
Mark Connolly began his career at RSM US LLP as a Supervisor from 2013 to 2016, where he managed audit engagements and client relationships. He also worked as an XBRL Research Assistant at the Financial Accounting Standards Board (FASB) from 2012 to 2013. His early experience includes an internship at PwC as an Audit Intern in 2010.
Education and Expertise
Mark Connolly earned a Bachelor’s Degree from the University of Connecticut, where he studied Accounting, Economics, and Environmental Economics from 2007 to 2011. His educational background provides a strong foundation in financial analysis and economic principles, which he applies in his strategic role within the biotechnology industry.